PubMed ID:
18571276
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
DOI:
https://doi.org/10.1016/j.jhep.2008.04.011
Authors:
Tavis JE,
Di Bisceglie A,
Yao E,
Donlin M,
Cannon N,
Wang P,
Yang H,
Tang G,
Wang D,
Rosen HR,
Burton JR,
Klarquist J,
Weston S,
Taylor MW,
Sanda C,
Tsukahara T,
Ferris M,
Belle SH,
Bilonick RA,
Block G,
Cline J,
Haritos M,
Im K,
Kelley S,
Kelsey S,
Koozer L,
Lawlor S,
Thomas SB,
Wahed A,
Wei Y,
Yee LJ,
Zhang S,
Robuck P,
Everhart J,
Hoofnagle JH,
Doo E,
Liang TJ,
Seeff LB,
Kleiner DE,
Rosen HR,
Ramcharran D,
Howell C,
Tong X,
Tang Y,
Rhodes SL,
Im K,
Su X,
Yee LJ,
Taylor MW,
Liang TJ,
Yang H,
Virahep-C Study Group,
Afdhal N,
Geahigan T,
Brown RS Jr,
Dove L,
Stovel S,
Martin M,
Terrault N,
Straley S,
Agudelo E,
Hinds M,
Heberlein J,
Wiley TE,
Williams M,
Howell CD,
Gibson K,
Callison K,
Lewis J,
Jeffers LJ,
Baker SM,
DeMedina M,
Hermitt C,
Conjeevaram HS,
Fontana RJ,
Harsh D,
Fried MW,
Smith SR,
Theodore D,
Zacks S,
Shrestha R,
Dougherty K,
Davis P,
Brown S
Studies:
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C
Interferon signaling pathway genes (IPGs) and interferon-stimulated genes (ISGs) are associated with the host response to hepatitis C virus (HCV) infection. We studied single nucleotide polymorphisms (SNPs) in IPGs and ISGs for their associations with response to pegylated interferon alpha-2a (Peg-IFN-alpha) plus ribavirin therapy in HCV genotype-1 infected patients.